Patents by Inventor Takashi Futamura

Takashi Futamura has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20160341740
    Abstract: Methods of diagnosing, confirming a diagnosis of, and determining a predisposition for a bipolar disorder in a subject are provided. An amount of at least one of biomarker from the cerebrospinal fluid and/or serum of a subject is measured, for example, isocitric acid. The amount of the at least one biomarker can be compared with a control amount of the at least one biomarker in a corresponding sample collected from a subject without the bipolar disorder. An increase or decrease in the amount of the particular biomarker or biomarkers measured can be indicative that the subject has the bipolar disorder or a predisposition for the bipolar disorder. Methods of identifying a compound for preventing and/or treating a bipolar disorder are also provided based on the expression level of an isocitric acid dehydrogenase 3 alpha and/or beta-subunit gene, and/or based on one or more metabolite biomarker.
    Type: Application
    Filed: May 17, 2016
    Publication date: November 24, 2016
    Applicant: National University Corporation Chiba University
    Inventors: Kenji Hashimoto, Takashi Futamura, Noriko Yoshimi, Takeo Yoshikawa, Yoshimi Iwayama, Mikael Landen
  • Publication number: 20150320698
    Abstract: This invention relates to the use of the phytocannabinoid cannabidivarin (CBDV) and combinations of the phytocannabinoid CBDV with tetrahydrocannabivarin (THCV) and cannabidiol (CBD) in the treatment of epilepsy. The invention further relates to the use of the phytocannabinoid CBDV in combination with standard anti-epileptic drugs (SAEDs). Preferably the SAED is one of ethosuximide, valproate or phenobarbital.
    Type: Application
    Filed: April 14, 2015
    Publication date: November 12, 2015
    Inventors: Ben Whalley, Claire Williams, Gary Stephens, Takashi Futamura
  • Patent number: 9125859
    Abstract: This invention relates to the use of the phytocannabinoid cannabidivarin (CBDV) and combinations of the phytocannabinoid CBDV with tetrahydrocannabivarin (THCV) and cannabidiol (CBD) in the treatment of epilepsy. The invention further relates to the use of the phytocannabinoid CBDV in combination with standard anti-epileptic drugs (SAEDs). Preferably the SAED is one of ethosuximide, valproate or phenobarbital.
    Type: Grant
    Filed: March 30, 2011
    Date of Patent: September 8, 2015
    Assignees: GW Pharma Limited, Otsuka Pharmaceutical Co., Limited
    Inventors: Ben Whalley, Claire Williams, Gary Stephens, Takashi Futamura
  • Publication number: 20120004251
    Abstract: This invention relates to the use of the phytocannabinoid cannabidivarin (CBDV) and combinations of the phytocannabinoid CBDV with tetrahydrocannabivarin (THCV) and cannabidiol (CBD) in the treatment of epilepsy. The invention further relates to the use of the phytocannabinoid CBDV in combination with standard anti-epileptic drugs (SAEDs). Preferably the SAED is one of ethosuximide, valproate or phenobarbital.
    Type: Application
    Filed: March 30, 2011
    Publication date: January 5, 2012
    Applicants: Otsuka Pharmaceutical Co., Limited, GW Pharma Limited
    Inventors: Ben Whalley, Claire Williams, Gary Stephens, Takashi Futamura
  • Publication number: 20030077678
    Abstract: According to the present invention, a diagnostic kit for schizophrenia was provided and the diagnostic kit comprises measurement of serum epidermal growth factor content using anti-epidermal growth factor antibody. The diagnosis kit according to this invention is useful for objective diagnosis of schizophrenia.
    Type: Application
    Filed: September 9, 2002
    Publication date: April 24, 2003
    Inventors: Hiroyuki Nawa, Takashi Futamura, Toshiyuki Someya, Koue Asama
  • Publication number: 20030056232
    Abstract: To provide a an animal with schizophrenic sensorimotor and behavioral abnormalities, a specific protein factor inhibiting development of brain function is administrated to a juvenile animal in the stage of its development and an animal exhibiting sensorimotor and behavioral abnormalities is prepared. As the sensorimotor and behavioral abnormalities observed in the animal of the present invention is very similar to schizophrenia, the animal is useful for development of an anti-schizophrenic medicine and a diagnostic agent for schizophrenia.
    Type: Application
    Filed: September 6, 2002
    Publication date: March 20, 2003
    Inventors: Hiroyuki Nawa, Takashi Futamura
  • Patent number: 6187774
    Abstract: The present invention relates to a fused heterocyclic compound of the formula (I) wherein each symbol is as defined in the specification, an optical isomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing a compound of the formula (I), an optical isomer thereof or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable additive, and a medicament containing a compound of the formula (I), an optical isomer thereof or a pharmaceutically acceptable salt thereof. The compound of the present invention is a useful antipsychotic agent effective not only for positive symptoms centering on hallucination and delusion characteristic of the acute stage of schizophrenia, but also negative symptoms of apathy, abulia and autism.
    Type: Grant
    Filed: September 3, 1998
    Date of Patent: February 13, 2001
    Assignee: Yoshitomi Pharmaceutical Industries, Ltd.
    Inventors: Hiroshi Tanaka, Takanobu Kuroita, Yoshifumi Togo, Seigo Ishibuchi, Masakazu Fujio, Takashi Futamura